Global marketsUpdated November 3

Pfizer raises its full-year outlook.

Demand for Pfizer’s newer medicines helped offset declining sales of its Covid products in the third quarter. Bloomberg reported that the company outperformed in the quarter and raised its full-year outlook. The Financial Times reported that revenue from non-Covid medicines rose 7%, including a blockbuster blood thinner. The shift is the point: Covid products are losing ground, but newer medicines are giving Pfizer another source of support.

2 publishers2 reports

Coverage started November 3